pirfenidone has been researched along with Emphysema in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azuma, A; Gemma, A; Inomata, M; Miura, Y; Nei, T; Saito, T; Saito, Y; Takoi, H; Tanaka, T; Yatagai, Y | 1 |
| De Jong, PA; De Raedt, N; Dupont, LJ; Gheysens, O; Ruttens, D; Van Raemdonck, DE; Vanaudenaerde, BM; Vandermeulen, E; Verleden, GM; Verleden, SE; Vos, R; Yserbyt, J | 1 |
2 other study(ies) available for pirfenidone and Emphysema
| Article | Year |
|---|---|
Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Topics: Aged; Antineoplastic Agents; Emphysema; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyridones; Retrospective Studies; Risk; Vital Capacity | 2018 |
Pirfenidone: a potential new therapy for restrictive allograft syndrome?
Topics: Allografts; Anti-Inflammatory Agents, Non-Steroidal; Emphysema; Fluorodeoxyglucose F18; Humans; Lung Transplantation; Male; Middle Aged; Positron-Emission Tomography; Postoperative Complications; Pulmonary Fibrosis; Pyridones; Radiopharmaceuticals; Syndrome; Tumor Necrosis Factor-alpha | 2013 |